Compare Medtronic PLC (MDT) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs PubMatic Inc — how do they compare? Medtronic PLC trades at $82.95 (market cap $106.61B), while PubMatic Inc trades at $12.85 (market cap $607.48M). The key difference: Medtronic PLC is far larger — about 175.5× PubMatic Inc's market cap, and Medtronic PLC pays a 3.46% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| MDT | PUBM | |
|---|---|---|
Market Cap | $106.61B | $607.48M |
Sector | Health | Technology |
52-Week High | $105.35 | $13.83 |
52-Week Low | $73.75 | $6.28 |
Enterprise Value | $125.36B | $504.98M |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
PUBM trades at $13.07, up 2.67% today, with a bullish technical signal from moving averages and oversold RSI conditions. The company reported a net loss of -$14.46M in 2025 despite beating Q1 2026 EPS estimates, with revenue at $282.93M. Recent news highlights product launches like AgenticOS and partnerships expanding its AI-powered ad tech reach, while analyst consensus is evenly split between Buy and Hold.
The outlook is mixed: strong cash flow and innovation in AI advertising support growth potential, but persistent negative margins and high P/E of 132 pose valuation risks. Upside exists if upcoming Q2 2026 earnings beat expectations, though competitive and macroeconomic pressures remain headwinds for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
